In the coming year, efficiency and automation will take center stage to maximize constrained resources but balancing sensible financial management with strategic investments will be vital.
Max Kelleher
Advertisement
Articles by Max Kelleher
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
FDA Approves Blenrep for Treatment of Replapsed/Refractory Multiple Myeloma
4
Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization
5
